CDX2 and malignant colon neoplasm: In 2016, Dalerba et al. published a study in The New England Journal of Medicine that showed that in addition to being associated with poor survival, a lack of CDX2 expression signature in colon cancer patients has been correlated with improved chemotherapy response.4